
PSA Chief Executive Carlos Tavares is confident a US$50 billion merger of the maker of Peugeot vehicles with Fiat Chrysler will proceed as planned and deliver synergies of at least €3.7 billion (US$4.2 billion).
The deal to create the world’s fourth-largest carmaker has become even more vital because of the impact of the coronavirus crisis and to speed up cost savings, Tavares told PSA’s annual shareholder meeting on Thursday, June 25.
“The merger with FCA is the best among the solutions to cope with the crisis and its uncertainties.”
Global car sales have slumped as measures to contain the coronavirus pandemic forced production lines to shut and showrooms to close, with carmakers scrambling to conserve cash in the industry’s worst since the 2008-09 financial crisis.
Tavares also played down fresh European Union antitrust scrutiny of the planned merger, adding that he was confident it would be finalised in the first quarter 2021 “at the latest.”
“The timetable of the merger with FCA is being strictly respected,” he said, adding that projected synergies of €3.7 billion from the deal was a “floor.”
EU antitrust regulators last week began a four-month investigation into the deal, claiming it may harm competition in small vans in 14 EU countries and Britain.
Full Content: Economic Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Government Suffers Third Successive Defeat on Data (Use and Access) Bill
May 20, 2025 by
CPI
Sex Toy Retailer Says Google Breaches EU Digital Market Rules
May 20, 2025 by
CPI
Latham & Watkins Expands Brussels Antitrust Team
May 20, 2025 by
CPI
Brazil’s Antitrust Watchdog Expected to Approve Pet Retail Merger Without Conditions
May 20, 2025 by
CPI
EU and UK Finalize Deal to Strengthen Antitrust Cooperation
May 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas